Nama's AI scorecard currently rates Immunome Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does IMNM report earnings?

Immunome's next scheduled report is on Nov 10, 2026. Analysts expect EPS of -$0.60.

What is the IMNM price target?

The median analyst price target from 15 analysts is $36.00, with a range of $24.00 – $40.00.

Is IMNM Shariah compliant?

Nama's AAOIFI-style screen reads Immunome as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Immunome (IMNM)

Healthcare · Biotechnology · NASDAQ

Immunome (IMNM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.21B and a free-cash-flow yield of -12.7%. Over the most recent reported fiscal year, revenue declined 23.2%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.7/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +23.2% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-39.6%

How far the last close sits under the highest price of the past five years.

Market cap	$2.21B
Trailing P/E	—
Price / book	4.0
Price / sales	—
FCF yield	-12.7%
Dividend yield	—
Gross margin	0.0%
Operating margin	0.0%
Net margin	0.0%
Revenue growth (YoY)	-23.2%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

IMNM earnings

Next report: Nov 10, 2026 (Q3 2026, EPS estimate -$0.60). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	-$0.65	-$0.50	-30.0%	$0
Q4 2025	Mar 3, 2026	-$0.76	-$0.57	-33.3%	$0
Q3 2025	Nov 6, 2025	-$0.65	-$0.54	-20.4%	$0
Q2 2025	Aug 6, 2025	-$0.50	-$0.50	+0.0%	$4.01M

IMNM analyst price target

Median target $36.00 from 15 analysts, ranging $24.00 – $40.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live IMNM data on Nama Insights →

IMNM FAQ

Is IMNM a buy?: Nama's AI scorecard currently rates Immunome Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does IMNM report earnings?: Immunome's next scheduled report is on Nov 10, 2026. Analysts expect EPS of -$0.60.
What is the IMNM price target?: The median analyst price target from 15 analysts is $36.00, with a range of $24.00 – $40.00.
Is IMNM Shariah compliant?: Nama's AAOIFI-style screen reads Immunome as Can't Tell. A figure the screen needs is missing, so it can't tell.